Kang Zhang
Auto-generated profile, based on publicly available information

Kang Zhang

Artificial Intelligence Cross Disciplinary Research Institute and Faculty of medicine, Macau University of Science and Technology, Macau, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Cell
Verified
Journal Article
Closed access
DKDaniel S. Kermany
Daniel S. Kermany
MGMichael Goldbaum
Michael Goldbaum
WCWenjia Cai
Wenjia Cai
CVCarolina C.S. Valentim
Carolina C.S. Valentim
HLHuiying Liang
Huiying Liang
KZKang Zhang
Kang Zhang

1 January 2013 in Molecular Cell
Verified
Journal Article
Closed access
GHGregory Hannum
Gregory Hannum
JGJustin Guinney
Justin Guinney
LZLing Zhao
Ling Zhao
LZLi Zhang
Li Zhang
GHGuy Hughes
Guy Hughes
KZKang Zhang
Kang Zhang

7 January 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JHJianxing He
Jianxing He
Sally BaxterSally Baxter
Sally Baxter
JXJie Xu
Jie Xu
JXJiming Xu
Jiming Xu
XZXingtao Zhou
Xingtao Zhou
KZKang Zhang
Kang Zhang

16 September 2015 in Nature
Verified
Journal Article
Open access
PDF file
CHChe-Ming J. Hu
Che-Ming J. Hu
RFRonnie H. Fang
Ronnie H. Fang
KWKuei-Chun Wang
Kuei-Chun Wang
BLBrian T. Luk
Brian T. Luk
STSoracha Thamphiwatana
Soracha Thamphiwatana
LZLiangfang Zhang
Liangfang Zhang
The authors report a new biomimetic nanodelivery platform in which polymeric nanoparticles enclosed in the plasma membrane of human platelets are used for disease-relevant targeting, and the therapeutic potential of the concept is demonstrated in animal models of coronary restenosis and systemic bacterial infection. The properties of blood platelets — small discoid cells that carry out a broad range of functions related to haemostasis — marks them out as prime candidates to form the basis of drug delivery systems. These authors report a new nanoparticle-based delivery platform, in which polymeric nanoparticles are enclosed in the plasma membrane of human platelets. They demonstrate the use of these platelet-membrane cloaked nanoparticles for antibiotic delivery in murine models for cardiovascular disease and systemic bacterial infection. Development of functional nanoparticles can be encumbered by unanticipated material properties and biological events, which can affect nanoparticle effectiveness in complex, physiologically relevant systems1,2,3. Despite the advances in bottom-up nanoengineering and surface chemistry, reductionist functionalization approaches remain inadequate in replicating the complex interfaces present in nature and cannot avoid exposure of foreign materials. Here we report on the preparation of polymeric nanoparticles enclosed in the plasma membrane of human platelets, which are a unique population of cellular fragments that adhere to a variety of disease-relevant substrates4,5,6,7. The resulting nanoparticles possess a right-side-out unilamellar membrane coating functionalized with immunomodulatory and adhesion antigens associated with platelets. Compared to uncoated particles, the platelet membrane-cloaked nanoparticles have reduced cellular uptake by macrophage-like cells and lack particle-induced complement activation in autologous human plasma. The cloaked nanoparticles also display platelet-mimicking properties such as selective adhesion to damaged human and rodent vasculatures as well as enhanced binding to platelet-adhering pathogens. In an experimental rat model of coronary restenosis and a mouse model of systemic bacterial infection, docetaxel and vancomycin, respectively, show enhanced therapeutic efficacy when delivered by the platelet-mimetic nanoparticles. The multifaceted biointerfacing enabled by the platelet membrane cloaking method provides a new approach in developing functional nanoparticles for disease-targeted delivery.

13 March 2020 in Nature Medicine
Verified
Journal Article
Closed access
YXYi Xu
Yi Xu
XLXufang Li
Xufang Li
BZBing Zhu
Bing Zhu
HLHuiying Liang
Huiying Liang
CFChunxiao Fang
Chunxiao Fang
SGSitang Gong
Sitang Gong

25 November 2019 in Genome Biology
Verified
Journal Article
Open access
PDF file
CBChristopher Bell
Christopher Bell
RLRobert Lowe
Robert Lowe
PAPeter D. Adams
Peter D. Adams
ABAndrea Baccarelli
Andrea Baccarelli
SBStephan Beck
Stephan Beck
VRVardhman K. Rakyan
Vardhman K. Rakyan
Epigenetic clocks comprise a set of CpG sites whose DNA methylation levels measure subject age. These clocks are acknowledged as a highly accurate molecular correlate of chronological age in humans and other vertebrates. Also, extensive research is aimed at their potential to quantify biological aging rates and test longevity or rejuvenating interventions. Here, we discuss key challenges to understand clock mechanisms and biomarker utility. This requires dissecting the drivers and regulators of age-related changes in single-cell, tissue- and disease-specific models, as well as exploring other epigenomic marks, longitudinal and diverse population studies, and non-human models. We also highlight important ethical issues in forensic age determination and predicting the trajectory of biological aging in an individual.